RTA 402 Phase 3 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Diabetic Kidney Disease)
Phase of Trial: Phase III
Latest Information Update: 20 Jun 2018
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Acronyms AYAME
- Sponsors Kyowa Hakko Kirin
- 05 Jun 2018 New trial record
- 04 Jun 2018 According to a Reata Pharmaceuticals media release, the study is expected to complete in Mar 2022.
- 04 Jun 2018 Status changed from planning to recruiting, according to a Reata Pharmaceuticals media release.